TPW reports consultancy for: Kite/a Gilead Company, Incyte, Sanofi. He has received research funding from: Syndax/Incyte, AlloVir, Kadmon/Sanofi. MS reports consultancy for: AbbVie, Genentech, AstraZeneca, Pharmacyclics, BeiGene, BMS, MorphoSys/Incyte, Kite, Eli Lilly, Genmab, Mustang Bio, Regeneron, ADC therapeutics, Fate Therapeutics, Janssen and MEI Pharma. He receives research funding: Mustang Bio, BMS, Pharmacyclics, Genentech, AbbVie,TG Therapeutics, BeiGene, AstraZeneca, Genmab, MorphoSys/Incyte, Vincerx. NA reports institutional research funding and consultancy fees from Kite/Gilead; and advisory board funds from Bristol Myers Squibb. JC reports consultancy for: Bristol Myers Squibb and Merit CRO. He serves as a data safety monitoring board member with ICON-Allovir and ICON-Prolacta. He owns stock in Actinium Pharmaceuticals, Bluebird Bio/2Seventy, Dynavax Technologies, aTyr Pharma, Gamida Cell Ltd, Novavax Inc, Ovid Therapeutics, Vaxart, and Veru. AC reports consultancy for: Elsevier, Kite and research funding from: Novartis, Fate Therapeutics, Kite, BMS. MJF reports consulting and advisory roles for Kite/Gilead, BMS, Novartis, JnJ/Legend. He reports research funding from Arcellx, Kite/Gilead, Novartis, Incyte. NG reports Honoraria from: Novartis, Kite, BMS, Caribou, Genentech, Janssen, Seagen, ADC Therapeutics. Brian Hill reports research funding and consultancy from Gilead, Novartis and BMS. TJ receives institutional research funding from” CTI Biopharma, Kartos therapeutics, Incyte, Bristol Myers Squibb; Advisory board participation with: Care Dx, Bristol Myers Squibb, Incyte, Abbvie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios pharma, Protagonist therapeutics; Education activity with Oncology APP, Binaytara Foundation, and ASH Highlights. JEM reports: research funding from Gilead, Atara, CRISPR, Precision Biosciences, and Scripps Research Institute. Dipenkumar Modi reports research funding from: Genentech, ADC Therapeutics, Karyopharm Therapeutics, Genmab. Consultancy: SeaGen, MorphoSys, ADC Therapeutics, Genmab. Honorarium: AstraZeneca, Beigene. MM reports consultancy from: AbbVie, CSL Behring. Peter Riedell reports consultancy and/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite/Gilead, Sana Biotechnology, Nektar Therapeutics, NurixTherapeutics, Intellia Therapeutics, CVS Caremark, Genmab, BeiGene, Janssen, and Pharmacyclics. He has received honoraria from Novartis. Research support from BMS, Kite Pharma, Novartis, MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech, and Tessa Therapeutics. AS report Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi. Research support: Takeda, BMS/Celgene.Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion. Speaker’s Bureau: Takeda. AH reports consultancy from: Bristol Myers Squibb, Genentech, Merck, Seattle Genetics, AstraZeneca, ADC Therapeutics, Takeda, Tubulis, Regeneron, Genmab, Pfizer, Caribou Biosciences, Adicet Bio, AddVie, Allogene Therapeutics. He reports research funding from: Bristol Myers Squibb, Genenetech, Merck, Seattle Genetics, KiTE Pharma, Gilead Sciences, AstraZeneca, ADC Therapeutics. CS has served as a paid consultant: Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. Mehdi Hamadani reports research support/Funding: Takeda Pharmaceutical Company; ADC Therapeutics; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, Genmab. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, BeiGene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. AJJ reports: research funding AbbVie. The other authors reported no conflicts of interest to disclose.